(TBPH) Theravance Biopharma - Ratings and Ratios

Theravance Biopharma, Inc. (NASDAQ: TBPH) is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative respiratory medicines. The company focuses on addressing chronic respiratory conditions, primarily in the United States and Europe. Its lead product, YUPELRI (revefenacin), is a once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of chronic obstructive pulmonary disease (COPD). The company also has a pipeline that includes Ampreloxetine, a norepinephrine reuptake inhibitor in Phase III development for neurogenic orthostatic hypotension (nOH), and TRELEGY, a combination therapy for COPD and asthma. Theravance Biopharma has established strategic partnerships, including a licensing agreement with Pfizer for its preclinical skin-selective pan-JAK inhibitor program and a collaboration with Viatris. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Based on the provided data, the 3-month forecast for Theravance Biopharma Inc. (NASDAQ: TBPH) suggests a mixed outlook. Technically, the stock is trading near its 20-day and 50-day moving averages ($9.37 and $9.39, respectively), with a 200-day moving average of $8.94, indicating potential support at higher levels. The ATR of 0.40 suggests moderate volatility. Fundamentally, the companys forward P/E of 11.21 indicates expectations of future earnings growth, though the current P/E is 0 due to negative profitability (RoE: -26.61). The P/S ratio of 7.25 reflects investor confidence in revenue growth. Over the next three months, the stock may experience sideways movement with potential upside if the company reports positive clinical trial results or strengthens its partnership pipeline. However, the high P/B ratio of 2.47 and negative profitability could weigh on investor sentiment.